menu
    • menu

    Company profile for Esperion Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Esperion is a pharmaceutical company that specializes in developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The Company has two late-stage therapies in development; both with confirmed regulatory pathways to approval and defined global pivotal Phase 3 clinical development plans. Bem...
    Esperion is a pharmaceutical company that specializes in developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The Company has two late-stage therapies in development; both with confirmed regulatory pathways to approval and defined global pivotal Phase 3 clinical development plans. Bempedoic acid and the Company’s lead product candidate, the bempedoic acid / ezetimibe combination pill, are targeted therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Esperion TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3891 Ranchero Drive Suite 150 Ann Arbor, MI 48108
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.esperion.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Esperion (ESPR) Reaches Settlement to Protect Nexletol Patents
    Esperion (ESPR) Reaches Settlement to Protect Nexletol Patents

    02 Jun 2025

    // GURUFOCUS

    https://www.gurufocus.com/news/2901186/esperion-espr-reaches-settlement-to-protect-nexletol-patents-espr-stock-news

    GURUFOCUS
    02 Jun 2025
    Share Share
    Esperion campaign sheds light on ‘Lipid Lurkers’ in artery walls
    Esperion campaign sheds light on ‘Lipid Lurkers’ in artery walls

    16 Jul 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/esperions-lipid-lurkers-campaign-sheds-light-high-ldl-cholesterol-hiding-artery-walls

    FIERCE PHARMA
    16 Jul 2024
    Share Share
    Enforcement Report - Week of April 24, 2024
    Enforcement Report - Week of April 24, 2024

    24 Apr 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-24-2024-1488.pdf

    FDA
    24 Apr 2024
    Share Share
    FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET®
    FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET®

    22 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240322544788/en

    BUSINESSWIRE
    22 Mar 2024
    Share Share
    CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe
    CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe

    22 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240322719062/en

    BUSINESSWIRE
    22 Mar 2024
    Share Share
    Esperion & Daiichi Sankyo Announce $125 Million Amendment to Their Collaboration
    Esperion & Daiichi Sankyo Announce $125 Million Amendment to Their Collaboration

    03 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240103960094/en

    BUSINESSWIRE
    03 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search